No definition available.
Other specified and unspecified disorders of iris and ciliary body
H7_IRISCILIARYNAS
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
142 |
4. Check minimum number of eventsNone |
142 |
5. Include endpointsNone |
142 |
6. Filter based on genotype QC (FinnGen only) |
142 |
Control definitions (FinnGen only)
- Control exclude
- H7_SCLERACORNEA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other specified and unspecified disorders of iris and ciliary body
based on the number of shared cases.
Similar with more cases:
- Other disorders of iris and ciliary body
- Disorders of sclera, cornea, iris and ciliary body
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 973 | 537 | 432 |
| Only index persons | 839 | 470 | 369 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.03 | 56.06 | 51.59 |
| Only index persons | 53.90 | 55.91 | 51.36 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 142 | 91 | 51 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 52.25 | 53.47 | 50.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 123
- Matched controls
- 1228
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H21.9
ICD-10 Finland
Disorder of iris and ciliary body, unspecified
+∞
64.3
56
*
H21.8
ICD-10 Finland
Other specified disorders of iris and ciliary body
+∞
60.5
53
*
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
+∞
20.4
19
*
H20.1
ICD-10 Finland
Chronic iridocyclitis
+∞
13.8
13
*
XCK10
NOMESCO Finland
Photography of fundus of eye
6.8
12.8
34
65
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
+∞
12.7
12
*
S01ED51
ATC
timolol, combinations; ophthalmic
9.7
12.7
26
33
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
12.3
10.7
19
18
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
15.1
10.0
16
12
CH2S4
NOMESCO Finland
Photography of iris
108.0
9.6
10
*
3648X
ICD-9 Finland
Disorders of iris and ciliary body, Other disorders of iris and ciliary body
+∞
8.4
8
*
S01EC01
ATC
acetazolamide; systemic
36.0
8.2
10
*
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
14.4
8.1
13
10
S01EA05
ATC
brimonidine; ophthalmic (sympathomimetics in glaucoma therapy)
14.4
8.1
13
10
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.0
7.7
33
104
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
14.6
7.6
12
9
D31.4
ICD-10 Finland
Benign neoplasm: Ciliary body
85.0
7.5
8
*
114
Kela drug reimbursment
Glaucoma
5.2
6.9
21
47
H26.2
ICD-10 Finland
Complicated cataract
18.0
6.9
10
6
Z96.1
ICD-10 Finland
Presence of intraocular lens
4.4
6.7
24
64
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.3
6.5
24
66
WX140
NOMESCO Finland
Parabulbar anesthesy
8.4
6.3
13
17
S01ED01
ATC
timolol; ophthalmic
8.4
6.3
13
17
H20.9
ICD-10 Finland
Iridocyclitis, unspecified
+∞
6.3
6
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.7
6.3
21
52
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
2.8
6.2
49
234
Mortality – FinRegistry
↥Association
Association between endpoint H7_IRISCILIARYNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_IRISCILIARYNAS | 1.164 [0.86, 1.58] | 0.327 |
| Birth year | 0.998 [0.99, 1.01] | 0.68 |
During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 413 females with H7_IRISCILIARYNAS died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have H7_IRISCILIARYNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.096% | No data |
| 5 | 0.77% | No data |
| 10 | 1.895% | No data |
| 15 | 3.663% | No data |
| 20 | 6.734% | No data |
Relationships between endpoints
↥Index endpoint: H7_IRISCILIARYNAS – Other specified and unspecified disorders of iris and ciliary body
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data